Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from CANbridge Pharmaceuticals Inc. ( (HK:1228) ) is now available.
CANbridge Pharmaceuticals Inc. announced that its product, velaglucerase-beta for injection (Gaurunning, CAN103), has received marketing approval in the PRC for treating type I and III Gaucher disease. This approval marks a significant milestone as Gaurunning is the first domestically developed enzyme replacement therapy for these conditions, potentially enhancing medication accessibility for patients in China and strengthening CANbridge’s position in the rare disease treatment market.
More about CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. is a global biopharmaceutical company based in the PRC, focusing on research, development, and commercialization of transformative therapies for rare diseases. The company has a diverse drug portfolio with three approved drugs and a pipeline targeting rare disease indications with unmet needs, such as Hunter syndrome, lysosomal storage disorders, and neuromuscular diseases. They are also developing gene therapies for rare genetic diseases like Duchenne muscular dystrophy.
Average Trading Volume: 1,287,214
Technical Sentiment Signal: Sell
Current Market Cap: HK$58.63M
For a thorough assessment of 1228 stock, go to TipRanks’ Stock Analysis page.